Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jin Medical International's EBIT per Share for the
six
months ended in Sep. 2025 was $0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $0.08.
During the past 12 months, the average EBIT per Share Growth Rate of Jin Medical International was -83.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -35.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -14.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Jin Medical International's EBIT per Share or its related term are showing as below:
ZJYL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -35 Med: 10.3 Max: 11
Current: -35
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Jin Medical International was 11.00% per year. The lowest was -35.00% per year. And the median was 10.30% per year.
ZJYL's 3-Year EBIT Growth Rate is ranked worse than 91.7% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.1
vs ZJYL: -35.00
Jin Medical International (NAS:ZJYL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Jin Medical International EBIT per Share Related Terms
Jin Medical International EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jin Medical International (ZJYL) has a EBIT per Share of $0.08 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jin Medical International and its competitors. According to the industry distribution chart, Jin Medical International ranks #630 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 91.7%.
Is Jin Medical International's EBIT per Share too high?
Jin Medical International's current EBIT per Share is $0.08. The Medical Devices & Instruments industry median EBIT per Share is 9.10. Jin Medical International's value of $0.08 is 99.1% below this industry median. Based on the distribution chart, Jin Medical International ranks #630 out of 687 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Jin Medical International has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jin Medical International's EBIT per Share compare to RVP and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Jin Medical International ranks #630 out of 687 companies for EBIT per Share. This places Jin Medical International in the lower half of its industry. The industry median EBIT per Share is 9.10. Jin Medical International's value of $0.08 is 99.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.10, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jin Medical International's current EBIT per Share of $0.08 is 99.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Jin Medical International and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jin Medical International's current EBIT per Share is $0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jin Medical International stock overvalued right now?
Based on GuruFocus' analysis, Jin Medical International (ZJYL) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.58, compared to a current price of $1.96 — trading 86.6% below its estimated fair value. The current EBIT per Share is $0.08 and 99.1% below the Medical Devices & Instruments industry median of 9.10. Jin Medical International's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Jin Medical International (ZJYL), the current EBIT per Share is $0.08 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jin Medical International (ZJYL) Overvalued in 2026?
Based on GuruFocus' analysis, Jin Medical International stock appears to be undervalued.
The current stock price of $1.96 is trading 86.6% below its estimated GF Value™ of $14.58.
GuruFocus considers Jin Medical International to be Significantly Undervalued.
Key valuation signals for ZJYL:
EBIT per Share: $0.08
GF Value™: $14.58 vs. price of $1.96 (86.6% below fair value)
Industry Position: 99.1% below the Medical Devices & Instruments median (#630 of 687)
No single metric tells the full story. See the ZJYL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
64GF Score
Get the complete analysis for ZJYL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZJYL has been successfully added to your 
